Challenges in the clinical development of PI3K inhibitors

Annals of the New York Academy of Sciences

Volumn 1280, Issue 1, 2013, Pages 19-23

  Massacesi, Cristian ^a   Di Tomaso, Emmanuelle ^b   Fretault, Nathalie ^a   Hirawat, Samit ^c  

^a Novartis Oncology   (France)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Patient selection; PI3K antagonists; PI3K inhibitors; Research design

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ABIRATERONE ACETATE; AROMATASE INHIBITOR; BEVACIZUMAB; BUPARLISIB; BYL 719; CRIZOTINIB; DOCETAXEL; ENZALUTAMIDE; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; INSULIN RECEPTOR SUBSTRATE 1; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METHODOLOGY; NONHUMAN; PATIENT SELECTION; PROSTATE CANCER; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE;

EID: 84875683453     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12060     Document Type: Article

References (11)

1. Bendell, J.C., J. Rodon, H.A. Burris, et al. 2012. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30: 282-290.
2. + metastatic breast cancer. J. Clin. Oncol. 30: 508 (abstract).
3. +/HER2- metastatic breast cancer (MBC). J. Clin. Oncol. 30: 510 (abstract).
4. Bretz, F., M. Posch, E. Glimm, et al. 2011. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biom. J. 53: 894-913.
5. Carver, B.S., C. Chapinski, J. Wongvipat, et al. 2011. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19: 575-586.
6. Maira, S.M., S. Pecchi, A. Huang, et al. 2012. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-Kinase inhibitor.Mol. Cancer Ther. 11: 317-328.
7. Engelman, J.A., L. Chen, X. Tan, et al. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14: 1351-1356.
8. Sos, M.L., M. Koker, B.A. Weir, et al. 2009. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69: 3256-3261.
9. Juric, D., J. Rodon, A.M. Gonzalez-Angulo, et al. 2012. BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research (March 31-April 4). Chicago, IL. AACR. Philadelphia (PA). Abstract nr CT-01.
10. Baselga, J., M. Campone, M. Piccart, et al. 2012. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New Engl. J. Med. 366: 520-529.
11. Markman, B., R. Dienstmann & J. Tabernero. 2010. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget. 1w: 530-543.